openPR Logo
Press release

Opioid Induced Constipation Treatment Market Research Report Forecast to 2015- 2023

01-13-2017 03:44 PM CET | Health & Medicine

Press release from: Transparency Market Research - Pharmaceutical

Opioid Induced Constipation Treatment Market Research Report

Global Opioid Induced Constipation Treatment Market: Snapshot

There are multiple drugs in the pipeline for opioid induced constipation treatment. Upon approval, these drugs will face little competition in this market which is largely untapped. There have not been many stable choices in the pharmaceutical industry for opioid induced constipation treatment over the recent past, but the continuous approval rate of highly targeted drugs is expected to provide a strong push to this market’s growth rate. This includes the PAMORA drugs that help treat OIC without intervening in the opioid’s action on the patient.

The opioid induced constipation treatment market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on the dosage form of the drug, type of drug class, and their geographical analysis. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises regulatory framework for major countries and event impact analysis. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global opioid induced constipation treatment market.

Mu-opioid Receptor Antagonists to Overtake Chloride Channel Activators by 2023

Till the end of 2016, chloride channel activators are expected to be the more popular drug class of opioid induced constipation treatments. This trend will continue for the coming years, but in time it is predicted that mu-opioid receptor antagonists will take the leading role among drug classes. A key reason for the popularity of chloride channel activators is the high level of sales of Amitiza ever since it was approved in 2013 and used specifically for opioid induced constipation treatment.

Over time, the growing number of mu-opioid receptor antagonists being approved and their greater efficacy over other drug classes is expected to push it to the top of the charts in terms of revenue generation before 2023. This drug class will also benefit from the increasing number of prescriptions being filed for opioid induced constipation treatments due to developments that reduce their side effects.

The leading providers of opioid induced constipation treatment include AstraZeneca, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant, Bayer, C.B. Fleet Company, Inc., Boehringer Ingelheim, Daewoong Co. Ltd., and Cosmo Pharmaceuticals.

Browse the full Opioid Induced Constipation Treatment Market: (Mu-opioid Receptor Antagonist, Chloride Channel Activator, and Others; Solid, Semi-solid, and Liquid): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2023 report at http://www.transparencymarketresearch.com/opioidinduced-constipation-treatment-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Opioid Induced Constipation Treatment Market Research Report Forecast to 2015- 2023 here

News-ID: 412734 • Views:

More Releases from Transparency Market Research - Pharmaceutical

Neurovascular Devices Market Business Opportunities and Growth Challenges Report
Neurovascular Devices Market Business Opportunities and Growth Challenges Report
Global Neurovascular Devices Market: Overview The global population is aging rapidly. According to WHO, the chances of health risks are greater in geriatric people than the young generation. Old age is considered to be one of the biggest risk factors that are responsible for developing various diseases such as cardiovascular and neurological conditions. It is because of these factors, the global neurovascular devices market is experiencing robust growth in the
Pneumococcal Vaccines Market anticipated expand at a CAGR of 3.3% from 2018 to 2026
Pneumococcal Vaccines Market anticipated expand at a CAGR of 3.3% from 2018 to 2 …
Transparency Market Research (TMR) has published a new report titled, “Pneumococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global pneumococcal vaccines market was valued at US$ 7,247.6 Mn in 2017 and is anticipated expand at a CAGR of 3.3% from 2018 to 2026. Increase in patient pool, growth of the pharmaceutical industry, government initiatives to increase vaccination programs, rise
Swab and Viral Transport Medium Market projected to expand at a CAGR of ~3% from 2020 to 2030
Swab and Viral Transport Medium Market projected to expand at a CAGR of ~3% from …
Swab and Viral Transport Medium Market: Introduction Transparency Market Research has published a new report titled, ‘Global Swab and Viral Transport Medium Market ’. According to the report, the global swab and viral transport medium market was valued at US$ 0.9 Bn in 2019 and is projected to expand at a CAGR of ~3% from 2020 to 2030. Viral transport medium (VTM) enables safe transfer of viruses, chlamydia, and mycoplasma for
Radiofrequency Ablation Devices Market by Product, Geography and Forecast to 202 …
Transparency Market Research (TMR) has published a new report titled, 'Radiofrequency Ablation Devices for Pain Management Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027'. According to the report, the global radiofrequency ablation devices for pain management market was valued at US$ 543.0 Mn in 2018 and is projected to expand at a CAGR of above 11.0% from 2019 to 2027. Overview Radiofrequency ablation is a minimally invasive surgical

All 5 Releases


More Releases for Opioid

Rising Opioid Use For Pain Management Fuels Growth In Opioid-Induced Constipatio …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Opioid-Induced Constipation Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market size for treatment of opioid-induced constipation has seen a substantial growth recently. It is expected to escalate from a solid $1.78 billion in 2024 to an impressive $1.9 billion in 2025, exhibiting
Growing Number Of Opioid Addiction Cases: Strategic Insights Driving Opioid Use …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Opioid Use Disorder (OUD) Market Size By 2025? The market size for opioid use disorder (OUD) has experienced a quick expansion in the past few years. The growth is projected to rise from $3.96 billion in 2024 to $4.39 billion in 2025, boasting a compound
Key Influencer in the Opioid-Induced Constipation Treatment Market 2025: Rising …
What combination of drivers is leading to accelerated growth in the opioid-induced constipation treatment market? The rise in opioid administration for cancer and non-cancer pain is expected to drive the growth of the opioid-induced constipation (OIC) treatment market. Opioids are commonly used for managing moderate to severe pain, but they can cause constipation. OIC treatments are vital for improving the quality of life for patients on opioids, allowing them to maintain
Top Factor Driving Opioid Use Disorder (OUD) Market Growth in 2025: Growing Numb …
How Are the key drivers contributing to the expansion of the opioid use disorder (oud) market? The rise in instances of opioid dependency is set to fuel the expansion of the opioid use disorder (OUD) market. Opioid dependency defines a health concern marked by habitual and uncontrolled opioid consumption which negatively impacts health. These opioids can generate feelings of bliss and relief from pain, but continued usage often results in tolerance
What's Driving the Opioid-Induced Constipation Treatment Market 2025-2034: Risin …
What Are the Projections for the Size and Growth Rate of the Opioid-Induced Constipation Treatment Market? The market size for treatments of constipation caused by opioids has seen robust growth lately. The forecasted growth indicates an increase from $1.78 billion in 2024 to $1.9 billion in 2025, representing a compound annual growth rate (CAGR) of 7.0%. This past growth is associated with a growing elderly population, individualized treatments for OIC, the
MEDICAL MARIJUANA AND THE OPIOID CRISIS
Marijuana from the Cannabis plant is classified as a psychoactive drug used for medical or recreational purposes. Although it has been used for decades, in the U.S., it is still illegal under federal law to use and possess marijuana. Get PDF Sample Brochure of this report at: https://decisionmarketreports.com/request-sample/1247622 Nevertheless, at the state level, policies regarding the medical and recreational use of Cannabis vary greatly, and in many states conflict significantly with federal